Cargando…
Estrogen stimulates female cancer progression by inducing myeloid-derived suppressive cells: investigations on pregnant and non-pregnant experimental models
OBJECTIVE: To investigate the clinical implications of 17β-estradiol (E2) in estrogen receptor α (ERα)-negative female cancer progression as well as the underlying biological mechanisms. METHODS: Clinical data from 306 locally-advanced cervical cancer (stage IIB-IVA) patients were analyzed in order...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443012/ https://www.ncbi.nlm.nih.gov/pubmed/30956772 http://dx.doi.org/10.18632/oncotarget.26711 |
_version_ | 1783407786580770816 |
---|---|
author | Kozasa, Katsumi Mabuchi, Seiji Matsumoto, Yuri Kuroda, Hiromasa Yokoi, Eriko Komura, Naoko Kawano, Mahiru Takahashi, Ryoko Sasano, Tomoyuki Shimura, Kotaro Kodama, Michiko Hashimoto, Kae Sawada, Kenjiro Nagasaka, Kazunori Kimura, Tadashi |
author_facet | Kozasa, Katsumi Mabuchi, Seiji Matsumoto, Yuri Kuroda, Hiromasa Yokoi, Eriko Komura, Naoko Kawano, Mahiru Takahashi, Ryoko Sasano, Tomoyuki Shimura, Kotaro Kodama, Michiko Hashimoto, Kae Sawada, Kenjiro Nagasaka, Kazunori Kimura, Tadashi |
author_sort | Kozasa, Katsumi |
collection | PubMed |
description | OBJECTIVE: To investigate the clinical implications of 17β-estradiol (E2) in estrogen receptor α (ERα)-negative female cancer progression as well as the underlying biological mechanisms. METHODS: Clinical data from 306 locally-advanced cervical cancer (stage IIB-IVA) patients were analyzed in order to investigate the relationships between age, serum E2 levels, and treatment outcomes. Clinical samples, ERα-negative cervical and breast cancer cell lines, and mouse xenograft models of cervical and breast cancers were employed in order to elucidate the mechanisms responsible for the E2- and pregnancy-mediated progression of cervical and breast cancers, with a focus on the role of myeloid-derived suppressor cells (MDSC). RESULTS: Younger patients with elevated E2 levels showed significantly shorter progression-free survival (P = 0.040) and overall survival (P = 0.039). The exogenous E2 treatment stimulated the mobilization of MDSC from bone marrow and directly augmented their suppressive activities, leading to the progression of ERα-negative cervical and breast cancers. The co-administration of an anti-Gr-1 neutralizing antibody with E2 prevented the E2-mediated induction of MDSC, and attenuated E2-mediated tumor growth in cervical and breast cancer xenografts. Significantly increased MDSC numbers and enhanced tumor growth were observed during pregnancy in mice with cervical or breast cancer. Significantly increased MDSC numbers were also observed during pregnancy in cervical cancer patients. CONCLUSIONS: E2 facilitates the progression of ERα-negative cervical or breast cancer under non-pregnant and pregnant conditions by inducing MDSC. MDSC inhibition therapy may have therapeutic efficacy in premenopausal or pregnant female cancer patients. |
format | Online Article Text |
id | pubmed-6443012 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-64430122019-04-05 Estrogen stimulates female cancer progression by inducing myeloid-derived suppressive cells: investigations on pregnant and non-pregnant experimental models Kozasa, Katsumi Mabuchi, Seiji Matsumoto, Yuri Kuroda, Hiromasa Yokoi, Eriko Komura, Naoko Kawano, Mahiru Takahashi, Ryoko Sasano, Tomoyuki Shimura, Kotaro Kodama, Michiko Hashimoto, Kae Sawada, Kenjiro Nagasaka, Kazunori Kimura, Tadashi Oncotarget Research Paper OBJECTIVE: To investigate the clinical implications of 17β-estradiol (E2) in estrogen receptor α (ERα)-negative female cancer progression as well as the underlying biological mechanisms. METHODS: Clinical data from 306 locally-advanced cervical cancer (stage IIB-IVA) patients were analyzed in order to investigate the relationships between age, serum E2 levels, and treatment outcomes. Clinical samples, ERα-negative cervical and breast cancer cell lines, and mouse xenograft models of cervical and breast cancers were employed in order to elucidate the mechanisms responsible for the E2- and pregnancy-mediated progression of cervical and breast cancers, with a focus on the role of myeloid-derived suppressor cells (MDSC). RESULTS: Younger patients with elevated E2 levels showed significantly shorter progression-free survival (P = 0.040) and overall survival (P = 0.039). The exogenous E2 treatment stimulated the mobilization of MDSC from bone marrow and directly augmented their suppressive activities, leading to the progression of ERα-negative cervical and breast cancers. The co-administration of an anti-Gr-1 neutralizing antibody with E2 prevented the E2-mediated induction of MDSC, and attenuated E2-mediated tumor growth in cervical and breast cancer xenografts. Significantly increased MDSC numbers and enhanced tumor growth were observed during pregnancy in mice with cervical or breast cancer. Significantly increased MDSC numbers were also observed during pregnancy in cervical cancer patients. CONCLUSIONS: E2 facilitates the progression of ERα-negative cervical or breast cancer under non-pregnant and pregnant conditions by inducing MDSC. MDSC inhibition therapy may have therapeutic efficacy in premenopausal or pregnant female cancer patients. Impact Journals LLC 2019-03-08 /pmc/articles/PMC6443012/ /pubmed/30956772 http://dx.doi.org/10.18632/oncotarget.26711 Text en Copyright: © 2019 Kozasa et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Research Paper Kozasa, Katsumi Mabuchi, Seiji Matsumoto, Yuri Kuroda, Hiromasa Yokoi, Eriko Komura, Naoko Kawano, Mahiru Takahashi, Ryoko Sasano, Tomoyuki Shimura, Kotaro Kodama, Michiko Hashimoto, Kae Sawada, Kenjiro Nagasaka, Kazunori Kimura, Tadashi Estrogen stimulates female cancer progression by inducing myeloid-derived suppressive cells: investigations on pregnant and non-pregnant experimental models |
title | Estrogen stimulates female cancer progression by inducing myeloid-derived suppressive cells: investigations on pregnant and non-pregnant experimental models |
title_full | Estrogen stimulates female cancer progression by inducing myeloid-derived suppressive cells: investigations on pregnant and non-pregnant experimental models |
title_fullStr | Estrogen stimulates female cancer progression by inducing myeloid-derived suppressive cells: investigations on pregnant and non-pregnant experimental models |
title_full_unstemmed | Estrogen stimulates female cancer progression by inducing myeloid-derived suppressive cells: investigations on pregnant and non-pregnant experimental models |
title_short | Estrogen stimulates female cancer progression by inducing myeloid-derived suppressive cells: investigations on pregnant and non-pregnant experimental models |
title_sort | estrogen stimulates female cancer progression by inducing myeloid-derived suppressive cells: investigations on pregnant and non-pregnant experimental models |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443012/ https://www.ncbi.nlm.nih.gov/pubmed/30956772 http://dx.doi.org/10.18632/oncotarget.26711 |
work_keys_str_mv | AT kozasakatsumi estrogenstimulatesfemalecancerprogressionbyinducingmyeloidderivedsuppressivecellsinvestigationsonpregnantandnonpregnantexperimentalmodels AT mabuchiseiji estrogenstimulatesfemalecancerprogressionbyinducingmyeloidderivedsuppressivecellsinvestigationsonpregnantandnonpregnantexperimentalmodels AT matsumotoyuri estrogenstimulatesfemalecancerprogressionbyinducingmyeloidderivedsuppressivecellsinvestigationsonpregnantandnonpregnantexperimentalmodels AT kurodahiromasa estrogenstimulatesfemalecancerprogressionbyinducingmyeloidderivedsuppressivecellsinvestigationsonpregnantandnonpregnantexperimentalmodels AT yokoieriko estrogenstimulatesfemalecancerprogressionbyinducingmyeloidderivedsuppressivecellsinvestigationsonpregnantandnonpregnantexperimentalmodels AT komuranaoko estrogenstimulatesfemalecancerprogressionbyinducingmyeloidderivedsuppressivecellsinvestigationsonpregnantandnonpregnantexperimentalmodels AT kawanomahiru estrogenstimulatesfemalecancerprogressionbyinducingmyeloidderivedsuppressivecellsinvestigationsonpregnantandnonpregnantexperimentalmodels AT takahashiryoko estrogenstimulatesfemalecancerprogressionbyinducingmyeloidderivedsuppressivecellsinvestigationsonpregnantandnonpregnantexperimentalmodels AT sasanotomoyuki estrogenstimulatesfemalecancerprogressionbyinducingmyeloidderivedsuppressivecellsinvestigationsonpregnantandnonpregnantexperimentalmodels AT shimurakotaro estrogenstimulatesfemalecancerprogressionbyinducingmyeloidderivedsuppressivecellsinvestigationsonpregnantandnonpregnantexperimentalmodels AT kodamamichiko estrogenstimulatesfemalecancerprogressionbyinducingmyeloidderivedsuppressivecellsinvestigationsonpregnantandnonpregnantexperimentalmodels AT hashimotokae estrogenstimulatesfemalecancerprogressionbyinducingmyeloidderivedsuppressivecellsinvestigationsonpregnantandnonpregnantexperimentalmodels AT sawadakenjiro estrogenstimulatesfemalecancerprogressionbyinducingmyeloidderivedsuppressivecellsinvestigationsonpregnantandnonpregnantexperimentalmodels AT nagasakakazunori estrogenstimulatesfemalecancerprogressionbyinducingmyeloidderivedsuppressivecellsinvestigationsonpregnantandnonpregnantexperimentalmodels AT kimuratadashi estrogenstimulatesfemalecancerprogressionbyinducingmyeloidderivedsuppressivecellsinvestigationsonpregnantandnonpregnantexperimentalmodels |